Literature DB >> 31616069

Nivolumab effective in oesophageal carcinoma.

Diana Romero1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31616069     DOI： 10.1038/s41571-019-0289-y

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  1 in total

1.  Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial.

Authors:  Ken Kato; Byoung Chul Cho; Masanobu Takahashi; Morihito Okada; Chen-Yuan Lin; Keisho Chin; Shigenori Kadowaki; Myung-Ju Ahn; Yasuo Hamamoto; Yuichiro Doki; Chueh-Chuan Yen; Yutaro Kubota; Sung-Bae Kim; Chih-Hung Hsu; Eva Holtved; Ioannis Xynos; Mamoru Kodani; Yuko Kitagawa
Journal:  Lancet Oncol       Date:  2019-09-30       Impact factor: 41.316
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.